315 related articles for article (PubMed ID: 21327910)
1. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of vasopressin receptor antagonists.
Ali F; Guglin M; Vaitkevicius P; Ghali JK
Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
[TBL] [Abstract][Full Text] [Related]
3. [Vasopressin receptor antagonists: the vaptans].
Villabona C
Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Izumi Y; Miura K; Iwao H
J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of vasopressin antagonists.
Costello-Boerrigter LC; Boerrigter G; Burnett JC
Heart Fail Rev; 2009 Jun; 14(2):75-82. PubMed ID: 18766438
[TBL] [Abstract][Full Text] [Related]
6. [Vasopressin antagonists in treatment of hyponatremia].
Olszewski W; Głuszek J
Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Ferguson JW; Therapondos G; Newby DE; Hayes PC
Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
[TBL] [Abstract][Full Text] [Related]
8. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
Verbalis JG
Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for hyponatremia in heart failure.
Goldsmith SR
Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
[TBL] [Abstract][Full Text] [Related]
10. Vasopressin-receptor antagonists in heart failure.
Schweiger TA; Zdanowicz MM
Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
Dahl E; Gluud LL; Kimer N; Krag A
Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
[TBL] [Abstract][Full Text] [Related]
12. [Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Dabrowska MD; Krysiak R; Okopień B
Wiad Lek; 2012; 65(1):19-30. PubMed ID: 22827112
[TBL] [Abstract][Full Text] [Related]
13. Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions.
Urso C; Brucculeri S; Caimi G
J Clin Pharm Ther; 2015 Aug; 40(4):376-85. PubMed ID: 25924179
[TBL] [Abstract][Full Text] [Related]
14. Letter: Vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis.
Karaahmet F; Coban S; Başar O; Yuksel O
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1103-4; author reply 1104. PubMed ID: 23130775
[No Abstract] [Full Text] [Related]
15. [Vasopressin receptor antagonists and heart failure].
Haass M
Ther Umsch; 2009 Nov; 66(11):735-40. PubMed ID: 19885790
[TBL] [Abstract][Full Text] [Related]
16. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
17. [Current options of treatment of hyponatremia].
Tesař V
Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin antagonists in heart failure.
Golestaneh L; Talreja A; Le Jemtel TH
Curr Heart Fail Rep; 2004 Dec; 1(4):190-6. PubMed ID: 16036044
[TBL] [Abstract][Full Text] [Related]
19. Management of hyponatremia.
Lee JJ; Kilonzo K; Nistico A; Yeates K
CMAJ; 2014 May; 186(8):E281-6. PubMed ID: 24344146
[No Abstract] [Full Text] [Related]
20. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
